IP Library Granted Patent US 8,852,872
Granted Patent B2
US 8,852,872 · App. 13/764,017 · Granted Oct 7, 2014

Methods for detecting oncofetal fibronectin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,852,872
App. No.
13/764,017
Granted
Oct 7, 2014
Kind
B2
Abstract

Methods and products for the detection of oncofetal fibronectin indicating molecules in samples are provided. Methods for imaging of oncofetal fibronectin are provided. In some methods provided herein, the sample is treated with a reagent and/or contacted with a non-specific binder. Provided are methods for testing subjects to ascertain health and disease status and to assess the risk of developing a disease or condition. Methods for detecting the presence of oncofetal fibronectin indicating molecules by a variety of methods such as immunoassays and mass spectrometry also are provided. Methods and products for detection of oncofetal fibronectin for selection of concepti are provided.

Claims (3)

1. A method for classifying the level of oncofetal fibronectin protein in a cervicovaginal sample, comprising: measuring the amount of oncofetal fibronectin protein in said sample taken from an asymptomatic patient at less than 25 weeks gestation, wherein the amount of oncofetal fibronectin protein in said sample is determined using the monoclonal antibody FDC-6;

comparing the amount of oncofetal fibronectin protein in said sample to a threshold level of 200 ng/ml;

and classifying the amount of oncofetal fibronectin protein in said sample according to said threshold level, whereby classification of oncofetal fibronectin protein in said sample above said threshold identifies a higher risk of preterm delivery.

Assignments (1)
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →